M H Voss1, A Hussain2, N Vogelzang3, J L Lee4, B Keam5, S Y Rha6, U Vaishampayan7, W B Harris8, S Richey9, J M Randall10, D Shaffer11, A Cohn12, T Crowell13, J Li13, A Senderowicz13, E Stone13, R Figlin14, R J Motzer15, N B Haas16, T Hutson17. 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York. Electronic address: mailto:vossm@mskcc.org. 2. Department of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore. 3. Department of Hematology/Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas; US Oncology Research, USA. 4. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul. 5. Department of Internal Medicine, Seoul National University Hospital, Seoul. 6. Department of Medicine, Severance Hospital, Seoul, Korea. 7. Department of Oncology, Karmanos Cancer Institute, Detroit. 8. Department of Hematology/Oncology, Emory University Winship Cancer Institute, Atlanta. 9. US Oncology Research, USA; Department of Medicine, Texas Oncology, Fort Worth. 10. Department of Medicine, University of California, San Diego, La Jolla. 11. US Oncology Research, USA; Department of Medicine, Albany Medical Center, NYOH, Albany. 12. US Oncology Research, USA; Department of Clinical Research, Rocky Mountain Cancer Centers, Denver. 13. Department of Medicine, Cerulean Pharma Inc., Waltham. 14. Department of Medicine, Cedars-Sinai Medical Center, Los Angeles. 15. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York. 16. Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia. 17. US Oncology Research, USA; Department of Medicine, Texas Oncology, Dallas, USA.
Abstract
BACKGROUND: Nanoparticle-drug conjugates enhance drug delivery to tumors. Gradual payload release inside cancer cells augments antitumor activity while reducing toxicity. CRLX101 is a novel nanoparticle-drug conjugate containing camptothecin, a potent inhibitor of topoisomerase I and the hypoxia-inducible factors 1α and 2α. In a phase Ib/2 trial, CRLX101 + bevacizumab was well tolerated with encouraging activity in metastatic renal cell carcinoma (mRCC). We conducted a randomized phase II trial comparing CRLX101 + bevacizumab versus standard of care (SOC) in refractory mRCC. PATIENTS AND METHODS: Patients with mRCC and 2-3 prior lines of therapy were randomized 1 : 1 to CRLX101 + bevacizumab versus SOC, defined as investigator's choice of any approved regimen not previously received. The primary end point was progression-free survival (PFS) by blinded independent radiological review in patients with clear cell mRCC. Secondary end points included overall survival, objective response rate and safety. RESULTS: In total, 111 patients were randomized and received ≥1 dose of drug (CRLX101 + bevacizumab, 55; SOC, 56). Within the SOC arm, patients received single-agent bevacizumab (19), axitinib (18), everolimus (7), pazopanib (4), sorafenib (4), sunitinib (2), or temsirolimus (2). In the clear cell population, the median PFS on the CRLX101 + bevacizumab and SOC arms was 3.7 months (95% confidence interval, 2.0-4.3) and 3.9 months (95% confidence interval 2.2-5.4), respectively (stratified log-rank P = 0.831). The objective response rate by IRR was 5% with CRLX101 + bevacizumab versus 14% with SOC (Mantel-Haenszel test, P = 0.836). Consistent with previous studies, the CRLX101 + bevacizumab combination was generally well tolerated, and no new safety signal was identified. CONCLUSIONS: Despite promising efficacy data on the earlier phase Ib/2 trial of mRCC, this randomized trial did not demonstrate improvement in PFS for the CRLX101 + bevacizumab combination when compared with approved agents in patients with heavily pretreated clear cell mRCC. Further development in this disease is not planned. CLINICAL TRIAL IDENTIFICATION: NCT02187302 (NIH).
BACKGROUND: Nanoparticle-drug conjugates enhance drug delivery to tumors. Gradual payload release inside cancer cells augments antitumor activity while reducing toxicity. CRLX101 is a novel nanoparticle-drug conjugate containing camptothecin, a potent inhibitor of topoisomerase I and the hypoxia-inducible factors 1α and 2α. In a phase Ib/2 trial, CRLX101 + bevacizumab was well tolerated with encouraging activity in metastatic renal cell carcinoma (mRCC). We conducted a randomized phase II trial comparing CRLX101 + bevacizumab versus standard of care (SOC) in refractory mRCC. PATIENTS AND METHODS: Patients with mRCC and 2-3 prior lines of therapy were randomized 1 : 1 to CRLX101 + bevacizumab versus SOC, defined as investigator's choice of any approved regimen not previously received. The primary end point was progression-free survival (PFS) by blinded independent radiological review in patients with clear cell mRCC. Secondary end points included overall survival, objective response rate and safety. RESULTS: In total, 111 patients were randomized and received ≥1 dose of drug (CRLX101 + bevacizumab, 55; SOC, 56). Within the SOC arm, patients received single-agent bevacizumab (19), axitinib (18), everolimus (7), pazopanib (4), sorafenib (4), sunitinib (2), or temsirolimus (2). In the clear cell population, the median PFS on the CRLX101 + bevacizumab and SOC arms was 3.7 months (95% confidence interval, 2.0-4.3) and 3.9 months (95% confidence interval 2.2-5.4), respectively (stratified log-rank P = 0.831). The objective response rate by IRR was 5% with CRLX101 + bevacizumab versus 14% with SOC (Mantel-Haenszel test, P = 0.836). Consistent with previous studies, the CRLX101 + bevacizumab combination was generally well tolerated, and no new safety signal was identified. CONCLUSIONS: Despite promising efficacy data on the earlier phase Ib/2 trial of mRCC, this randomized trial did not demonstrate improvement in PFS for the CRLX101 + bevacizumab combination when compared with approved agents in patients with heavily pretreated clear cell mRCC. Further development in this disease is not planned. CLINICAL TRIAL IDENTIFICATION: NCT02187302 (NIH).
Authors: Roy van der Meel; Einar Sulheim; Yang Shi; Fabian Kiessling; Willem J M Mulder; Twan Lammers Journal: Nat Nanotechnol Date: 2019-11-06 Impact factor: 39.213
Authors: Keith T Schmidt; Cody J Peer; Alwin D R Huitema; Monique D Williams; Susan Wroblewski; Jan H M Schellens; Ravi A Madan; William D Figg Journal: J Pharm Biomed Anal Date: 2019-12-27 Impact factor: 3.935
Authors: Keith T Schmidt; Fatima Karzai; Marijo Bilusic; Lisa M Cordes; Cindy H Chau; Cody J Peer; Susan Wroblewski; Alwin D R Huitema; Jan H M Schellens; James L Gulley; William L Dahut; William D Figg; Ravi A Madan Journal: Oncologist Date: 2022-09-02 Impact factor: 5.837
Authors: KirkE Hevener; Tatsiana A Verstak; Katie E Lutat; Daniel L Riggsbee; Jeremiah W Mooney Journal: Acta Pharm Sin B Date: 2018-07-25 Impact factor: 11.413